a lesson in marketing, page-3

Ithingham,

The article gives plenty of information about how much royalties BTA is likely to get from Simcere sales.

Here’s the link:

http://news.xinhuanet.com/english/2009-02/06/content_10772564.htm

Quote: “GSK reportedly licensed Chinese companies to produce Zanamivir in 2006 but it did not offer related techniques to make the drug. It also needs to be approved by Chinese authorities for sale in the country.”

And:

"Test procedures for the drug Zanamivir are still being decided. It would take a long time to complete the clinical trials," said Xu Xiaoping, a member of the institute.”

The above was announced in 2009. How much Relenza will Simcere manufactures for sales? Is it not obvious?

This is the “normalised” GSK relationship for which Peter Cook GSK was rewarded 452,000 free share options.

If you want more information how hard GSK is marketing Relenza, here’s more information:

http://www.hotcopper.com.au/post_single.asp?fid=1&tid=944330&msgno=4288237